Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

LUPIN LTD.

NSE : LUPINBSE : 500257ISIN CODE : INE326A01037Industry : Pharmaceuticals & DrugsHouse : Lupin

BSE1943.854.45 (+0.23 %)

PREV CLOSE ( ) 1939.40

OPEN PRICE ( ) 1935.15

BID PRICE (QTY) 1942.80 (1610)

OFFER PRICE (QTY) 1944.50 (7)

VOLUME 15880

TODAY'S LOW / HIGH ( )1935.15 1970.00

52 WK LOW / HIGH ( )1774 2403.45

NSE1942.903.7 (+0.19 %)

PREV CLOSE( ) 1939.20

OPEN PRICE ( ) 1941.90

BID PRICE (QTY) 1942.00 (38)

OFFER PRICE (QTY) 1942.90 (10)

VOLUME 126360

TODAY'S LOW / HIGH( ) 1940.60 1970.00

52 WK LOW / HIGH ( )1795.2 2402.9

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 01-03 1983

Management Info

Manju D Gupta - Chairman Nilesh Gupta - Managing Director

Registered Office

Address Kalpataru Inspire, 3rd Floor,Off. Western Express Highway,Santacruz (East),
Mumbai,
Maharashtra-400055

Phone 022 66402323

Email info@lupin.com

Website www.lupin.com

Registrars Details

MUFG Intime India Pvt Ltd.

C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai

Listing : BSE, NSE

NEWS

03Sep Lupin gets USFDA’s nod for Risperidone
Lupin has received approval from the United States Food and Drug Adminis..

29Aug Lupin informs about updates
Lupin has informed that Crisil ESG Ratings & Analytics (‘Crisil ESG..

20Aug Lupin launches Bosentan Tablets for Or
Lupin has launched Bosentan Tablets for Oral Suspension, 32 mg in the Un..

20Aug Lupin informs about press release
Lupin has informed that it enclosed a Press Release as regards, the Comp..

12Aug Lupin partners with Sandoz Group AG
Lupin has partnered with Sandoz Group AG (Sandoz), Switzerland, to marke..

Financials

Rs. in Millions

	QTR Jun 25	ANNUAL 25
Net Profit	21280.7	39729.6
Gross Profit	25881.5	48371.2
Operating Profit	27837.8	56465.3
Net Sales	57085.9	169675

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Neuland Laboratories (BSE) 14995.00 (2.67%)	M.Cap ( in Cr)18879.12
Astrazeneca Pharma I (BSE) 9201.05 (1.23%)	M.Cap ( in Cr)23002.63
Procter&Gamble Healt (BSE) 6520.00 (0.92%)	M.Cap ( in Cr)10822.80
Acutaas Chemicals (BSE) 1484.40 (4.14%)	M.Cap ( in Cr)12069.12
Glenmark Pharma (BSE) 2048.40 (2.90%)	M.Cap ( in Cr)57362.96

Shareholding Pattern

	PROMOTERS	46.9%
	MUTUAL FUNDS/UTI	19.35%
	NON-INSTITUTION	6.28%
	FI/BANKS/INSURANCE	4.64%
	GOVERNMENT	0%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
Tata Nifty MidSmall...	7.93
Motilal Oswal Nifty...	7.88
Nippon India Pharma...	6.07
ICICI Pru Nifty Pha...	5.93
Nippon India Nifty ...	5.92
HDFC Pharma and Hea...	5.60
Mirae Asset Healthc...	5.18

Risk Disclosures on Derivatives

Smart Quotes

LUPIN LTD.